Nodule outcomes based on primary malignancy
| Primary malignancy | Total no of patients | No (%) of patients with malignant nodules | Type of malignant nodule | |||
|---|---|---|---|---|---|---|
| No (%) of patients with metastatic nodules | No (%) of patients with lung cancers | No (%) of patients with second primary cancers | No (%) of patients where primary site undetermined | |||
| *One patient with chondrosarcoma had both metastatic disease and primary lung cancer and was included in both categories. | ||||||
| †All tumour types were analysed individually. Because some patients had more than one primary tumour, the sum of all figures in a given column may exceed that reported as the total. | ||||||
| Group 1 | ||||||
| Head/neck | 11 | 9 (82%) | 2 (22%) | 6 (67%) | 0 (0%) | 1 (11%) |
| Group 2 | ||||||
| Bladder | 12 | 4 (33%) | 0 (0%) | 4 (100%) | 0 (0%) | 0 (0%) |
| Breast | 64 | 16 (25%) | 10 (63%) | 5 (31%) | 1 (6%) | 0 (0%) |
| Cervix | 1 | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Oesophagus | 2 | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) |
| Ovary | 2 | 1 (50%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Prostate | 15 | 8 (53%) | 1 (13%) | 7 (89%) | 0 (0%) | 0 (0%) |
| Subtotal | 96 | 31 (32%) | 12 (39%) | 17 (55%) | 1 (3%) | 1 (3%) |
| Group 3 | ||||||
| Colon | 15 | 8 (53%) | 3 (38%) | 5 (62%) | 0 (0%) | 0 (0%) |
| Rectum | 4 | 3 (75%) | 3 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Liver | 1 | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Carcinoid | 1 | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Adrenal | 1 | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Kidney | 6 | 2 (33%) | 2 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Uterus | 6 | 2 (33%) | 1 (50%) | 1 (50%) | 0 (0%) | 0 (0%) |
| Subtotal | 34 | 18 (53%) | 10 (56%) | 8 (44%) | 0 (0%) | 0 (0%) |
| Group 4 | ||||||
| Thymus | 1 | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Melanoma | 8 | 4 (50%) | 1 (25%) | 2 (50%) | 1 (25%) | 0 (0%) |
| Sarcoma* | 7 | 2 (33%) | 2 (67%) | 1 (33%) | 0 (0%) | 0 (0%) |
| Testes | 4 | 1 (25%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Kaposi’s sarcoma | 2 | 1 (50%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Subtotal | 22 | 9 (41%) | 5 (50%) | 4 (40%) | 1 (10%) | 0 (0%) |
| Total*† | 151 | 64 (42%) | 28 (44%) | 32 (50%) | 2 (3%) | 2 (3%) |